Seastar Medical Receives FDA Approval To Begin Study With Selective Cytopheretic Device To Reduce Hyperinflammation In Adults With Acute Kidney Injury

Media coverage

• Title	Seastar Medical Announces Details Of The Selective Cytopheretic Device Pivotal Study In Critically Ill Adults With Acute Kidney Injury
  Media name/outlet	MENAFN -Press Releases (English)
  Country/Territory	Jordan
  Date	15/02/23
  Persons	Kevin Chung

• Title	Seastar Medical Receives FDA Approval To Begin Study With Selective Cytopheretic Device To Reduce Hyperinflammation In Adults With Acute Kidney Injury
  Media name/outlet	MENAFN -Press Releases (English)
  Country/Territory	Jordan
  Date	9/02/23
  Persons	Kevin Chung